Parenchymal FLAIR hyperintensity before thrombolysis is a prognostic factor of ischemic stroke outcome at 3 Tesla

J Neuroradiol. 2015 Oct;42(5):269-77. doi: 10.1016/j.neurad.2015.04.008. Epub 2015 May 27.

Abstract

Background: The goal of the present study was to determine whether the presence or absence of parenchymal FLAIR hyperintensity alone, before thrombolysis, might be a predictive factor of ischemic stroke outcomes after the acute phase of stroke and at 3 months.

Materials and methods: We retrospectively included 84 patients with an ischemic stroke between November 2007 and March 2012, who underwent 3T MRI, were treated by thrombolysis, and had medical follow-up at 3 months. Two readers analyzed parenchymal FLAIR visibility. Logistic regressions were performed for NIHSS difference (NIHSS at admission - NIHSS at the end of hospitalization) and for 3 months modified Ranking Score (mRS). Predictive values of positive parenchymal FLAIR for identifying poor outcome at discharge and at 3 months were estimated.

Results: Parenchymal FLAIR positivity was not predictive of NIHSS difference but it predicted poor outcome at 3 months (sensitivity: 0.49 [0.37-0.60], specificity: 0.69 [0.46-0.91], positive predictive value: 0.87 [0.76-0.98] and negative predictive value: 0.24 [0.12-0.36]).

Conclusions: At 3 Tesla, the presence of a parenchymal hyperintense FLAIR signal before thrombolysis is predictive of a poor clinical outcome at 3 months.

Keywords: Acute stroke; Assessments; Magnetic resonance imaging; Patient outcomes; Prognosis; Therapeutic thrombolysis.

MeSH terms

  • Aged
  • Brain / pathology*
  • Female
  • France / epidemiology
  • Humans
  • Magnetic Resonance Imaging / methods*
  • Male
  • Middle Aged
  • Outcome Assessment, Health Care / methods
  • Prevalence
  • Prognosis
  • Reproducibility of Results
  • Retrospective Studies
  • Risk Assessment / methods
  • Risk Factors
  • Sensitivity and Specificity
  • Stroke / drug therapy
  • Stroke / mortality*
  • Stroke / pathology*
  • Survival Rate
  • Thrombolytic Therapy / mortality*